AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 54(2), 1996, pp. 140-145
Copyright © 1996 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Homeida, M. M. A.
Right arrow Articles by Bennett, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Homeida, M. M. A.
Right arrow Articles by Bennett, J. L.

The Effectiveness of Annual Versus Biennial Mass Chemotherapy in Reducing Morbidity Due to Schistosomiasis: A Prospective Study in Gezira-Managil, Sudan

Mamoun M. A. Homeida, Isam A. Eltoum, Magdi M. Ali, Suad M. Suliaman, Elshiekh A. Elobied, Mahmoud Mansour, Ahmed M. Saad AND James L. Bennett
Department of Medicine, Department of Pathology, and Department of Surgery, Faculty of Medicine, Khartoum, Sudan; Tropical Institute, National Health Laboratory, Khartoum, Sudan; Bilharzia Research Unit, National Health Laboratory, Khartoum, Sudan; Bilharzia Research Unit, Brigham Young University-Sudan-Medical Research Center Research Project, National Health Laboratory, Khartoum, Sudan; Department of Pharmacology, Michigan State University, East Lansing, Michigan

The most serious complication of schistosomiasis is periportal fibrosis, which affects a large number of subjects in endemic areas. Population-based chemotherapy remains the most effective way of controlling this disease. In an attempt to find the best way to deliver chemotherapy to the endemic population, we compared the impact of repeated annual versus biennial mass chemotherapy on morbidity due to schistosomiasis in two villages in Gezira, Sudan. One village was given five rounds of mass chemotherapy annually in the years 1990–1994 while the other village was given three rounds of mass chemotherapy biennially from 1988 to 1994. Before treatment, these villages had similar intensity of infection and prevalence. One round of either annual or biennial treatment reduced the intensity of infection, but not prevalence or morbidity. After two rounds of annual chemotherapy, infection rates, bloody diarrhea, and fibrosis in those 20 years of age and less were significantly reduced. Two rounds of biennial chemotherapy had a similar effect on rates and bloody diarrhea; however, fibrosis was reduced only after the third round of biennial chemotherapy. Prevalence of hepatosplenomegaly increased after both treatment regimens. Reinfection was most prominent in those 5–14 years of age. These findings support the general notion that repeated chemotherapy may be needed in areas of high transmission of schistosomiasis. We recommend two rounds of annual mass chemotherapy to significantly reduce infection and morbidity.




This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
N. Berhe, B. Myrvang, and S. G. Gundersen
Reversibility of Schistosomal Periportal Thickening/Fibrosis after Praziquantel Therapy: A Twenty-Six Month Follow-up Study in Ethiopia
Am J Trop Med Hyg, February 1, 2008; 78(2): 228 - 234.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Society of Tropical Medicine and Hygiene.